MCM
VIRX

MAI Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

MAI Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,018
Closed -$647 – 3622
2024
Q4 		$647 Buy
+4,018
New +$791 ﹤0.01% 3272
2024
Q3 		– Sell
-27,417
Closed -$14.9K – 1258
2024
Q2 		$14.9K Sell
27,417
-336,680
-92% -$266K ﹤0.01% 1222
2024
Q1 		$371K Buy
364,097
+8,637
+2% +$6.31K ﹤0.01% 904
2023
Q4 		$203K Sell
355,460
-42,210
-11% -$25.9K ﹤0.01% 1021
2023
Q3 		$414K Buy
397,670
+90,100
+29% +$122K 0.01% 698
2023
Q2 		$434K Sell
307,570
-71,898
-19% -$103K 0.01% 697
2023
Q1 		$603K Sell
379,468
-47,448
-11% -$86.2K 0.01% 572
2022
Q4 		$623K Sell
426,916
-210,725
-33% -$615K 0.01% 545
2022
Q3 		$2.72M Sell
637,641
-10,309
-2% -$43.7K 0.05% 221
2022
Q2 		$2.51M Buy
647,950
+267,162
+70% +$761K 0.05% 224
2022
Q1 		$1.81M Buy
+380,788
New +$1.15M 0.03% 285

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

MAI Capital Management's VIRX Position: Q1 2025 in Review

MAI Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 4,018 shares — an estimated $647 sold.

MAI Capital Management first reported a position in VIRX in Q1 2022 and held it in 11 quarters. The position peaked at $2.72M in Q3 2022. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • MAI Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • MAI Capital Management sold 4,018 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $647.
  • MAI Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2022 and held it in 11 quarters.
  • MAI Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2.72M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on MAI Capital Management's 13F filing for Q1 2025, filed 15 May 2025.